The effect of natural killer (NK) cell alloreactivity on the outcome of unrelated hematopoietic SCT (HSCT) remains a topic of debate. NK cell alloreactivity after allogeneic HSCT is regulated by killer-cell Ig-like receptors (KIRs). To investigate the influence of KIRs on outcome after unrelated HSCT, we retrospectively analyzed the HLA and KIR genotypes of 116 donorrecipient pairs. We found that missing KIR ligands in recipients were significantly associated with a decreased leukemic relapse risk (P ¼ 0.019, HR ¼ 0.329), mainly in myeloid disease (P ¼ 0.003, HR ¼ 0.193). This beneficial effect was seen in AML/myelodysplastic syndrome and also in chronic myeloid leukemia. In myeloid disease, missing KIR ligands also improved 5-year OS (P ¼ 0.034, HR ¼ 0.430) and disease-free survival (DFS) (P ¼ 0.024, HR ¼ 0.445). Meanwhile, the presence of donor-activating KIR2DS3 gene was associated with increased relapse risk (P ¼ 0.003, HR ¼ 5.046), decreased OS (P ¼ 0.004, HR ¼ 3.181) and DFS (P ¼ 0.003, HR ¼ 2.919) in myeloid disease. No effect was seen in patients with lymphoid disease. Our study indicated that, in unrelated HSCT for myeloid leukemia, missing KIR ligands in recipients offered a lower relapse risk and a long-term survival advantage. The presence of KIR2DS3 in the donor was an important risk factor for myeloid leukemia.
Introduction
Allogeneic hematopoietic SCT (HSCT) is a successful curative therapy for a variety of hematological malignancies. The success of allogeneic HSCT partly depends on the GVL effect caused by donor lymphocytes. Apart from alloreactive T cells, alloreactive natural killer (NK) cells also have an important role in the induction of a GVL effect after HSCT. 1, 2 Natural killer cells possess the ability to kill cells that are undergoing tumorigenesis or infection by viruses or internal pathogens without previous stimulation. [3] [4] [5] [6] NK cell function is determined by signaling through several receptor families, including activating and inhibitory killer-cell Ig-like receptors (KIRs). 7 NK cells are mainly regulated negatively by inhibitory KIRs that recognize groups of HLA class I alleles. The inhibitory KIRs with identified HLA ligands are as follows: KIR2DL2/KIR2DL3, which bind group 1 HLA-C molecules (HLA-C1) characterized by serine at position 77 and asparagine at position 80; KIR2DL1, which recognizes group 2 HLA-C molecules (HLA-C2) characterized by asparagine 77 and lysine 80; KIR3DL1, which recognizes the HLA-Bw4 alleles; and KIR3DL2, which recognizes the HLA-A3 and A11 alleles. 8 In the setting of HSCT, NK cell alloreactivity can be used to induce a GVL reaction. Accordingly, some clinical data have confirmed that NK cell alloreactivity in the graft vs host (GVH) direction can reduce relapse rate and prolong OS after HSCT in patients with AML, 1,2,9 chronic myeloid leukemia (CML), 9 ,10 myelodysplastic syndrome (MDS) 9 and childhood acute lymphoid leukemia (ALL). 1 However, other studies have arrived at the opposite conclusion, particularly in unrelated donor HSCT (URD-HSCT), and have shown a deleterious effect of NK cell alloreactivity. 11 Natural killer cell alloreactivity (see above) was based on the KIR ligand mismatch model, also known as the ligandligand model. It is known, however, that the KIR genes, which are located on human chromosome 19q13. 4 , and the HLA genes, which are located on human chromosome 6, segregate independently of each other in normal Mendelian fashion. This allows for the possibility of persons who lack KIR receptors for their HLA ligands and, vice versa, that is, persons who lack HLA ligands for their KIR receptors.
Subsequently, a second model known as the receptorligand model (or missing ligand model) was proposed, in which the consideration is on the KIR genotype rather than the ligand of the donor's KIR and whether its corresponding ligand is missing in the recipient. There are several reports retrospectively analyzing transplant outcome on the basis of this model, with some showing an advantage in certain aspects, for example OS, 13, 14 relapse-free survival and 13-15 TRM, 13, 16 whereas others failed to find any beneficial effects. These discrepancies are probably linked to heterogeneous patient populations, differences in the sources of stem cells and various conditioning regimens. 17, 18 In addition to the inhibitory KIRs and HLA class I molecules, the potential clinical significance of activating KIRs, for which the ligands and functions are not well identified, 19 is receiving increasing attention. The presence of the KIR2DS2 gene in the donor has been associated with a high risk of mortality following URD-HSCT, 20 whereas the presence of two activating KIRs, 2DS1 and 2DS2, in the donor has been significantly associated with a decreased leukemic relapse rate. 8 Moreover, a recently published study has shown that another activating KIR gene, KIR2DS5, is associated with leukemia-free survival after HSCT in CML patients. 21 Nevertheless, the role of activating KIRs in HSCT still needs further exploration.
Killer-cell Ig-like receptor genes exhibit haplotypic variability, especially in terms of the number and type of genes present on a given haplotype. In general, KIR haplotypes divide simply into two functionally distinctive groups, namely, A and B. 22, 23 Group A has a fixed number of genes that encode inhibitory receptors, with the exception of 2DS4, whereas group B, which are mostly activating KIR genes, exhibit much more variability in the number of KIR genes. These KIR haplotypes also affect the clinical outcomes of HSCT, but the impacts are variedly or sometimes inconsistently reported. 18, 24, 25 On the basis of the above controversy and discrepancy, the present study investigated a panel of 116 patients at our center with different hematological malignancies and the effect of KIR genes and missing KIR ligands on the clinical outcome of URD-HSCT.
Patients, materials and methods

Healthy donors and patients
The study included 116 patients with hematological malignancies who underwent URD-HSCT between February 2001 and May 2008. Disease types included myeloid (AML, CML and MDS) and lymphoid (ALL) leukemias. Patients and their donors provided written informed consent and the institutional review board of Zhejiang University Institute of Hematology approved this study. Characteristics of the donors and patients are given in Table 1 .
Patients with all lymphoid diseases received myeloablative conditioning, but 16 patients with myeloid diseases (mainly CML) were treated with a reduced-intensity regimen. Antithymocyte globulin (ATG) was used in 25 patients before transplantation, 22 of whom had myeloid diseases. The pre-transplantation risk category included standard or high risk. Acute leukemia (complete remission 1, CR1) or CML (chronic phase 1), as well as MDS classified as refractory anemia or refractory anemia with ringed sideroblasts were categorized as standard risk (n ¼ 86), whereas acute leukemia 4CR1, CML in advanced phase, MDS classified as refractory anemia with excess of blasts were considered as high risk (n ¼ 30).
HLA and KIR typing
Patient and donor DNA was prepared from peripheral blood and BM mononuclear cells before transplantation. HLA-A, HLA-B and HLA-DRB1 Ags were determined by PCR sequence-specific probe (PCR-SSP) (Lifecodes Corporation, Stamford, CT, USA). HLA-C loci genes were analyzed using a PCR-SSP kit (Invitrogen Dynal, Brown Deer, WI, USA). HLA-C and HLA-B alleles were segregated into the epitope groups, namely, HLA-C group 1, HLA-C group 2 and HLA-Bw4. KIR genotype analysis was performed by the PCR-SSP technique, using a KIR genotyping PCR-SSP kit (Invitrogen Dynal). KIR genotyping was performed according to methods described previously. 26 Missing KIR ligand algorithm Donor-recipient pairs were divided into two categories based on the presence or absence of recipient HLA ligand for KIR2DL1, KIR2DL2/KIR2DL3 and KIR3DL1. Missing KIR ligands were defined as the absence of one or more recipient HLA epitopes for the corresponding donor-inhibitory KIRs. 14 
Haplotype assignment
Samples containing either one (A/B heterozygotes) or two (B/B homozygotes) group B haplotypes were assigned the genotype designation B/x. Samples that lacked all KIR B loci were assigned the genotype A/A.
Statistical analysis
All 116 transplant patients were included in the analysis of four end points: OS, DFS, TRM and grade II-IV acute GVHD (aGVHD). The associations between patient characteristics or pre-transplantation variables and post transplantation outcomes were calculated by the KaplanMeier method, and compared with the log-rank test. In univariate and multivariate analysis, Cox regression was used. Factors included in univariate analysis were age, disease stage, HLA match, KIR haplotype, missing KIR ligands, type of conditioning, patient and donor sex, stem cell source, diagnosis, CD34 þ cell count, HLA-C alleles of recipients (heterozygous C1/C2 and homozygous C1 or C2), HLA-Bw alleles of recipients and donor-activating KIR genes. Factors identified as significant (Po0.1) on univariate analysis were then entered into the multivariate Cox proportional hazards regression analysis. Po0.05 was considered statistically significant. Analyses were performed using SPSS software version 13.0 (Chicago, IL, USA).
Results
Patient characteristics
Patient and donor characteristics are listed in Table 1 . Patients in the lymphoid disease group had a slightly lower median age. A total of 111 out of 116 patients achieved engraftment and complete donor chimerism after transplantation. The median follow-up time was 26 months (range, 10-92 months). The KIR gene frequencies detected in the donors are in line with frequencies from other Asian populations. [26] [27] [28] Either conditioning regimen or GVHD prophylaxis regimen had no significant effect on transplant outcome. aGVHD aGVHD was diagnosed and graded according to internationally accepted criteria. 29 The incidence of grade II-IV aGVHD for all patients was 25%, and for myeloid and lymphoid groups, the incidence was 21.8 and 33.3%, respectively. There was no difference in the incidence of aGVHD between the patients who were transplanted with missing KIR ligands and those with all ligands (27.5 vs 16%; P ¼ 0.23). In the 25 patients who received antithymocyte globulin before transplantation, the cumulative risk of GVHD was not significantly lower in the patients with missing KIR ligands than all ligands (6.2 vs 12.5%, P ¼ 0.58). Multivariate analysis showed that PBSCs were predictive of aGVHD (HR ¼ 2.332, P ¼ 0.03) ( Table 2 ).
In the lymphoid disease group, multivariate analysis showed that older patients tended to have an increased incidence of aGVHD (HR ¼ 1.080, P ¼ 0.029). In the myeloid disease group, however, no significant factors were seen for the development of aGVHD.
Relapse
At the time of last follow-up, the cumulative incidence of relapse among all the patients was 21.8%. For the myeloid and lymphoid disease groups, the incidence of relapse was 19.4 and 25.2%, respectively. In the myeloid disease group, the cumulative risk of relapse was lower in the patients with missing KIR ligands than all ligands (10.7 vs 41.5%, P ¼ 0.002; Figure 1a ). This effect of the missing KIR ligands on relapse was comparably significant between the AML/MDS subgroup (12.6 vs 40%, P ¼ 0.03) and CML subgroup (4 vs 41.7%, P ¼ 0.008). For standard-risk myeloid leukemia, patients with missing KIR ligands resulted in a lower relapse rate than patients with all ligands, although no statistical significance was reached (11.3 vs 26%, P ¼ 0.356). For high-risk myeloid leukemia, the risk of relapse in patients with missing KIR ligands was significantly lower than that in patients with all ligands (9.1 vs 71.4%, P ¼ 0.002). Furthermore, the impact of missing KIR ligands was found mainly in the HLA-matched group (13.9 vs 62.5%, P ¼ 0.001) and KIR haplotype, B/x group (11.5 vs 55%, P ¼ 0.01). For lymphoid diseases, there was no significant difference in relapse rate between the patients with missing KIR ligands and those with all ligands (P ¼ 0.344). As shown in Table 2 , multivariate analysis indicated that the presence of missing KIR ligands was still a protective factor for prevention of relapse (HR ¼ 0.329, P ¼ 0.019). Other significant factors that might have increased relapse risk included more activating KIR genes in the donor (HR ¼ 1.463, P ¼ 0.005), as it significantly increased the rate of relapse (P ¼ 0.016; Figure 1b) . A/A in the donor significantly decreased the cumulative incidence of relapse compared with B/x (12.9 vs 28.6%, P ¼ 0.024).
In the myeloid disease group, the presence of missing KIR ligands was the only protective factor for relapse (HR ¼ 0.193, P ¼ 0.003). The presence of donor-activating KIR2DS3 was the only risk factor for relapse (HR ¼ 5.046, P ¼ 0.003), as it significantly increased the cumulative incidence of relapse (46.4 vs 11.6%, P ¼ 0.003; Figure 1c ). In the lymphoid disease group, multivariate analysis showed the high-risk disease to be the only risk factor for relapse (HR ¼ 5.340, P ¼ 0.031).
OS and DFS
The 5-year estimated OS and DFS were 60.9 and 50.6%, respectively. The corresponding rates were 63.6 and 54.5% for the myeloid disease group, and 55.6 and 42.7% for the lymphoid disease group. We found no significant influence of missing KIR ligands on survival in the patients with lymphoid diseases. However, for myeloid diseases, patients with missing KIR ligands had improved OS (72.2 vs 42.4%, P ¼ 0.027; Figure 2a ) and DFS (63.6 vs 32.8%, P ¼ 0.022; Figure 2b ) compared with the patients with all ligands. In a multivariate analysis of myeloid diseases, missing KIR ligands remained one of the independent factors for improving OS (HR ¼ 0.430, P ¼ 0.034) and DFS (HR ¼ 0.445, P ¼ 0.024). Another prognostic factor for survival was donor-activating KIR2DS3. The presence of donor-activating KIR2DS3 led to a significant decrease in the 5-year OS rate (35 vs 72.1%, P ¼ 0.004; HR ¼ 3.181; 
Transplant-related mortality
The cumulative incidence of treatment-related mortality was 23.5% for all patients after HSCT. In the myeloid and lymphoid groups, TRM was 20.2 and 30.4%, respectively. There was no significant effect of missing KIR ligands or any donor-activating KIRs on TRM, which indicated that NK alloreactivity, according to the receptor-ligand model, did not influence TRM. In the multivariate analysis model, HLA mismatch was the only risk factor against TRM (HR ¼ 2.333, P ¼ 0.035). In the lymphoid disease group, older age of the recipient was associated with a significantly higher TRM (HR ¼ 1.071, P ¼ 0.021). However, in the myeloid disease group, we found no significant influence of all the studied factors on TRM.
Discussion
According to the hypothesis of 'missing self' proposed by Karre et al., 30 KIR ligand mismatch in the GVH direction could activate donor NK cells and lead to NK alloreactivity in the clinical situation, 2,9,10 in which HLA disparity between donors and recipients fulfills the criterion of 'missing self'. While KIRs are located on chromosome 19q13.4, the genes that encode HLA molecules are located on a different chromosome. Independent segregation of HLA and KIR genes raises the possibility that persons exhibit HLA ligands for which they have no KIR and vice versa.
Another algorithm, termed the 'missing ligand' or 'receptor-ligand' model, has therefore been proposed for predicting clinical outcome. 14, 31, 32 Because most individuals have inhibitory KIRs for HLA-C1, C2 and Bw4, we explored a model based on recipient HLA typing alone to determine KIR ligand status. This is possibly the first such analysis for a Chinese patient population for unrelated donor stem cell transplants. We hope to provide further data concerning the impact of missing KIR ligands on unrelated donor stem cell transplants.
In the present study, we examined whether the interaction between donor KIR and patient HLA genotypes had an impact on the outcome after URD-HSCT within separate disease categories. For patients with AML, CML and MDS, missing KIR ligands in the recipient led to prolonged DFS and OS, through a decrease in relapse, which indicated that missing KIR ligands were associated with a marked GVL effect in myeloid disease. However, in lymphoid disease, no beneficial effect was observed in our study. This clinical finding agreed with the in vitro observation that some histotypes of lymphoid disease, such as common B ALL, are resistant to NK alloreactive killing. The resistance was considered to be associated with lack of expression of leukocyte function-associated Ag-1 33 and/or MHC class I chain-related gene A/B in ALL cells. 34 The OS after transplantation is influenced not only by leukemia relapse but also by TRM resulting from graft failure, fatal infections, severe aGVHD or chronic GVHD. We observed that missing KIR ligands did not reduce TRM but slightly increased mortality, especially in lymphoid disease, compared with KIR ligand match (34.2 vs 0%, P ¼ 0.187). The higher TRM was mainly caused by increasing infectious complications. One explanation for the higher infection risk is that alloreactive NK cells interfere with effective immunity to infection by eliminating recipient APCs. 35 Natural killer alloreactivity is associated with decreased occurrence of aGVHD in T-cell-depleted transplantation. 2 In our patients, the majority of whom received non-T-celldepleted conditioning, missing KIR ligands did not show any beneficial effect on aGVHD. Although alloreactive NK cells can eliminate recipient APCs, which have been shown to initiate aGVHD, 2 the donor T cells were active immediately after transplantation and established aGVHD before NK cells had the opportunity to kill host APCs. Meanwhile, NK cell effects were obscured by the immunosuppression necessary to prevent or control GVHD caused by donor T cells. Even in the 25 patients who received in vivo T-cell-depleted transplants, the benefit was not as obvious as T-cell-depleted haploidentical transplantation. One possible explanation is that T-cell depletion in these patients was partial, as administration of antithymocyte globulin in vivo only achieved a 2-3 log depletion, compared with the more extensive (4-5 log) in vitro T-cell depletion in haplotype-mismatched transplantations. Cooley 25 has reported that donor B/x, which mainly consisted of activating KIRs, reduced post transplant relapse and improved relapse-free survival in patients with AML. 25 Conversely, in our study, A/A, not B/x, and a low number of donor-activating KIR genes conferred a decreased relapse risk. In multivariate Cox analysis, a low number of donor-activating KIR genes were identified as one independent protecting factor against relapse. Our observation was similar to that in two other recent studies. 24, 36 The possible mechanism for these effects is that more activating KIRs expressed on donor NK cells lead to alloaggression of the graft toward the host. This in turn impairs immune reconstitution in recipients, and then hampers an effective GVL response.
We analyzed the effect of any single activating KIR gene on transplant outcome. Only the presence of donor KIR2DS3 was found to increase relapse risk and decrease long-term survival in myeloid diseases. The other activating KIR genes had no prognostic impact (data not shown). Similarly, Schellekens et al. 37 have confirmed the effect of donor KIR2DS3 on relapse after HLA-identical sibling transplantation. 37 The difference is that they further described the absence of KIR2DS3 in the donor, and the presence of this gene in the patient was also associated with a higher relapse rate in unrelated transplantation. 38 As for GVHD, the effect of donor KIR2DS3 is still controversial. In HLA-identical sibling transplantation, the presence of KIR2DS3 in the donor has been identified as an independent protective factor against chronic GVHD.
36
However, for patients receiving unrelated transplants, donor KIR2DS3 has been reported to increase aGVHD. 39 In our study, we did not find any association between this gene and aGVHD in unrelated transplantation. These conflicting results are difficult to explain, as the function and ligand specificity of KIR2DS3 have to date not been identified.
In summary, missing KIR ligands in URD-HSCT of our single center is associated with prolonged survival and decreased relapse risk for myeloid disease. However, missing KIR ligands adds no benefits in reducing aGVHD and TRM. Our study helps to identify clinical settings in which selection of donors with missing KIR ligands may offer a long-term survival advantage, but further prospective studies involving larger numbers of patients are necessary to confirm our observations.
